Artoss, Inc.

Artoss, Inc. manufactures NanoBone, a bone graft substitute based on nanotechnology that leverages the body's natural healing capacity. The product features an Amorphous Silica Gel (ASG) matrix that is replaced by autologous organic matrix within 14 days of implantation, creating an osteogenic microenvironment. Clinical data demonstrates healing comparable to autograft with lower complication rates, achieving radiographic and clinical healing within 8 weeks. NanoBone is supplied as a ready-to-use putty with superior handling characteristics, requiring no preparation or mixing. Primary applications include trauma cases, fracture repair, bone defects, and fusion procedures. The product is positioned as a cost-effective alternative to BMP and stem cell-containing products, eliminating the risks and morbidity associated with autograft harvesting. Regulatory pathway and specific FDA clearance status not detailed on site. The company targets orthopedic surgeons and trauma specialists, with clinical validation from peer-reviewed studies and surgeon testimonials.